Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Buy” by Analysts

Xencor, Inc. (NASDAQ:XNCR) has earned a consensus rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $34.88.

XNCR has been the topic of a number of research analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, Wells Fargo & Company started coverage on shares of Xencor in a research report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price for the company.

Insiders Place Their Bets

In other news, Director Alan Bruce Montgomery sold 1,421 shares of Xencor stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at $247,054.20. The trade was a 13.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the completion of the sale, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at $8,487,443.05. This represents a 12.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 67,366 shares of company stock worth $1,664,908. Company insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in Xencor by 147.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after buying an additional 1,858,440 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Xencor in the third quarter worth about $11,563,000. RTW Investments LP bought a new stake in Xencor during the 3rd quarter valued at approximately $11,563,000. Braidwell LP bought a new stake in Xencor during the 3rd quarter valued at approximately $9,380,000. Finally, Erste Asset Management GmbH purchased a new position in Xencor in the 3rd quarter worth approximately $7,087,000.

Xencor Price Performance

XNCR stock opened at $17.04 on Monday. The stock’s 50 day simple moving average is $22.23 and its 200 day simple moving average is $20.98. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a 12-month low of $15.31 and a 12-month high of $27.24.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.